Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Europe Approvals

GW Pharma Among Myriad Hopefuls Seeking Extended Indications In EU

  • News

Executive Summary

Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.

You may also be interested in...



First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod

New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.

GSK's Belantamab Among Drugs Seeking EU Approval Nod

GlaxoSmithKline's potential multiple myeloma treatment is one of several new products that could get an EU marketing thumbs up from the European Medicines Agency this week.

New Zealand To Create New Regulator Under Therapeutic Product Reform Bill

After 10 years in the making, draft legislation for modernizing how medicines and medical devices are regulated in New Zealand has been introduced in parliament for debate.

Table

View full table

Topics

Related Companies

Tags:
Drug Review Europe Approvals
Latest News

New Zealand To Create New Regulator Under Therapeutic Product Reform Bill

Global Pharma Guidance Tracker – November 2022

Food For Thought On US FDA Reforms

FDA’s Win-Win: More Comprehensive IND Safety Reports With Minimal Effort Due To Harmonization

See All
UsernamePublicRestriction

Register

PS142583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By